Stock Analysis on Net
Stock Analysis on Net
Microsoft Excel LibreOffice Calc

Eli Lilly & Co. (NYSE:LLY)

Analysis of Revenues

Advanced level

Revenues as Reported

Eli Lilly & Co., Income Statement, Revenues

US$ in thousands

Microsoft Excel LibreOffice Calc
12 months ended: Dec 31, 2019 Dec 31, 2018 Dec 31, 2017 Dec 31, 2016 Dec 31, 2015
Endocrinology 12,814,400  11,702,100  10,085,200  8,082,800  7,036,800 
Oncology 4,614,400  4,260,500  3,811,900  3,721,800  3,509,800 
Immunology 1,793,300  1,140,000  605,100  113,100  — 
Neuroscience 1,722,900  1,820,700  2,171,000  2,720,300  2,935,400 
Cardiovascular —  2,254,300  2,871,100  3,225,400  3,068,000 
Other human pharmaceutical products 1,374,400  235,600  241,400  200,500  227,700 
Human pharmaceutical products 22,319,400  21,413,200  19,785,700  18,063,900  16,777,700 
Animal health products —  3,142,500  3,085,600  3,158,200  3,181,000 
Revenue 22,319,400  24,555,700  22,871,300  21,222,100  19,958,700 

Based on: 10-K (filing date: 2020-02-19), 10-K (filing date: 2019-02-19), 10-K (filing date: 2018-02-20), 10-K (filing date: 2017-02-21), 10-K (filing date: 2016-02-19).

Item Description The company
Revenue Amount of revenue recognized from goods sold, services rendered, insurance premiums, or other activities that constitute an earning process. Includes, but is not limited to, investment and interest income before deduction of interest expense when recognized as a component of revenue, and sales and trading gain (loss). Eli Lilly & Co.’s revenue increased from 2017 to 2018 but then decreased significantly from 2018 to 2019.